Tanya Ramey

532 total citations
13 papers, 370 citations indexed

About

Tanya Ramey is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, Tanya Ramey has authored 13 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 6 papers in Experimental and Cognitive Psychology and 3 papers in Psychiatry and Mental health. Recurrent topics in Tanya Ramey's work include Treatment of Major Depression (7 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (6 papers) and Stress Responses and Cortisol (2 papers). Tanya Ramey is often cited by papers focused on Treatment of Major Depression (7 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (6 papers) and Stress Responses and Cortisol (2 papers). Tanya Ramey collaborates with scholars based in United States, Australia and Denmark. Tanya Ramey's co-authors include Carla Yunis, Chad D. Morris, Robert M. Anthenelli, Cristina Russ, Sarah Dubrava, Philip T. Ninan, Jeff Musgnung, J. Miceli, David Keller and Eduard Vieta and has published in prestigious journals such as Annals of Internal Medicine, The Journal of Clinical Psychiatry and Drug and Alcohol Dependence.

In The Last Decade

Tanya Ramey

12 papers receiving 360 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tanya Ramey United States	8	126	114	105	100	58	13	370
Maxime Barakat Canada	8	207 1.6×	103 0.9×	55 0.5×	64 0.6×	26 0.4×	19	455
Mary Hauser United States	11	86 0.7×	110 1.0×	45 0.4×	29 0.3×	37 0.6×	20	327
Simone Bolognesi Italy	12	46 0.4×	98 0.9×	37 0.4×	46 0.5×	56 1.0×	34	380
Barjot Gill Canada	9	99 0.8×	45 0.4×	64 0.6×	24 0.2×	31 0.5×	12	351
I Maany United States	12	94 0.7×	132 1.2×	51 0.5×	57 0.6×	101 1.7×	20	557
Joan Buttenfield United States	8	82 0.7×	172 1.5×	22 0.2×	77 0.8×	21 0.4×	10	363
Giada Benasi United States	9	101 0.8×	108 0.9×	44 0.4×	101 1.0×	39 0.7×	19	334
ReJoyce Green United States	12	70 0.6×	25 0.2×	78 0.7×	83 0.8×	37 0.6×	39	450
Jan‐Henry Stenberg Finland	11	65 0.5×	190 1.7×	32 0.3×	108 1.1×	19 0.3×	32	398
Ileana Pacheco‐Colón United States	12	216 1.7×	79 0.7×	25 0.2×	47 0.5×	13 0.2×	25	363

Countries citing papers authored by Tanya Ramey

Since Specialization

Citations

This map shows the geographic impact of Tanya Ramey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tanya Ramey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tanya Ramey more than expected).

Fields of papers citing papers by Tanya Ramey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tanya Ramey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tanya Ramey. The network helps show where Tanya Ramey may publish in the future.

Co-authorship network of co-authors of Tanya Ramey

This figure shows the co-authorship network connecting the top 25 collaborators of Tanya Ramey. A scholar is included among the top collaborators of Tanya Ramey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tanya Ramey. Tanya Ramey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Keyser‐Marcus, Lori, James M. Bjork, Amanda Adams, et al.. (2023). Development and clinical feasibility study of a brief version of an addiction‐focused phenotyping battery in females receiving buprenorphine for opioid use disorder. Brain and Behavior. 13(8). e3128–e3128. 3 indexed citations

2.

McIntyre, Roger S., Nicole D. Anderson, Bernhard T. Baune, et al.. (2019). Expert Consensus on Screening and Assessment of Cognition in Psychiatry. CNS Spectrums. 24(1). 154–162. 22 indexed citations

3.

Kleykamp, Bethea A., Marta De Santis, Robert H. Dworkin, et al.. (2019). Craving and opioid use disorder: A scoping review. Drug and Alcohol Dependence. 205. 107639–107639. 43 indexed citations

4.

Ninan, Philip T., et al.. (2015). Incidence and Timing of Taper/Posttherapy–Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder. The Primary Care Companion For CNS Disorders. 17(1). 6 indexed citations

5.

Khan, Arif, et al.. (2014). Abrupt Discontinuation Compared With a 1-Week Taper Regimen in Depressed Outpatients Treated for 24 Weeks With Desvenlafaxine 50 mg/d. Journal of Clinical Psychopharmacology. 34(3). 365–368. 22 indexed citations

6.

Fava, Maurizio, et al.. (2014). A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Augmentation of a Nicotinic Acetylcholine Receptor Partial Agonist in Depression. Journal of Clinical Psychopharmacology. 35(1). 51–56. 14 indexed citations

7.

Nichols, Alice I., Shannon L. Lubaczewski, Yali Liang, et al.. (2014). Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects. International Journal of Clinical Pharmacology and Therapeutics. 52(10). 830–841. 6 indexed citations

8.

Anthenelli, Robert M., Chad D. Morris, Tanya Ramey, et al.. (2013). Effects of Varenicline on Smoking Cessation in Adults With Stably Treated Current or Past Major Depression. Annals of Internal Medicine. 1 indexed citations

9.

Clayton, Anita H., Susan G. Kornstein, Boadie W. Dunlop, et al.. (2013). Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder. The Journal of Clinical Psychiatry. 74(10). 1010–1017. 48 indexed citations

10.

Anthenelli, Robert M., Chad D. Morris, Tanya Ramey, et al.. (2013). Effects of Varenicline on Smoking Cessation in Adults With Stably Treated Current or Past Major Depression. Annals of Internal Medicine. 159(6). 390–400. 104 indexed citations

11.

Rickels, Karl, et al.. (2012). Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. International Clinical Psychopharmacology. 27(3). 142–150. 44 indexed citations

12.

Miceli, J., et al.. (2009). P.4.a.015 Adjunctive pregabalin after partial response to SSRI or SNRI in GAD: results of a double-blind, placebo-controlled trial. European Neuropsychopharmacology. 19. S593–S594. 1 indexed citations

13.

Vieta, Eduard, et al.. (2008). Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. Journal of Psychopharmacology. 24(4). 547–558. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact